A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsors the ongoing Phase 3 ACTG A5379 clinical study.
- Read more about Three-dose hepatitis B vaccine regimen protects people with HIV
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/three-dose-hepatitis-b-vaccine-regimen-protects-people-with-hiv
No comments:
Post a Comment